ARTICLE | Clinical News
Vitaxin: Updated Phase II data
May 23, 2005 7:00 AM UTC
Updated preliminary data from an open-label, international Phase II trial in 112 patients showed a 1-year survival rate of 53% in the Vitaxin alone group vs. 42% for the Vitaxin plus DTIC (dacarbazine...